|
|
|
|
|
|
|
Novocure Ltd Ord Sh (NVCR)
|
|
25.05 0.4 (1.62%)
|
04-23 16:00
|
|
Open:
|
24.85
|
Pre. Close:
|
24.65
|
|
High:
|
25.45
|
Low:
|
24.8
|
|
Volume:
|
783,229
|
Market Cap:
|
2264M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
25.479 - 25.58
|
25.58 - 25.667
|
|
Low:
|
24.521 - 24.646
|
24.646 - 24.753
|
|
Close:
|
24.836 - 25.038
|
25.038 - 25.212
|
|
|
|
Technical analysis (as of: 2018-04-23 4:31:53 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a BUY today, upgraded from lower rating. This stock seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.
|
|
Target:
|
Six months: 30.02 One year: 35.06
|
|
Support:
|
Support1: 21.90 Support2: 19.55
|
|
Resistance:
|
Resistance1:
25.70 Resistance2: 30.02
|
|
Pivot:
|
21.99
|
|
Moving Averages:
|
MA(5): 24.35 MA(20): 21.79
MA(100): 21.20 MA(250): 19.01
|
|
MACD:
|
MACD(12,26):
0.79 Signal(12,26,9): 0.31
|
|
%K %D:
|
%K(14,3): 86.99 %D(3): 86.03
|
|
RSI:
|
RSI(14): 69.29
|
|
52-Week:
|
High: 25.7
Low: 10.5 Change(%): 131.9
|
|
Average Vol(K):
|
3-Month: 90302
10-Days 137352
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.NVCR has closed below upper band by 7.6%. Bollinger Bands are 166.8% wider than normal. The large width of the bands suggest high volatility as compared to NVCR's normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue.
|
|
|
Headline News
|
|
2018-04-22T12:57:43-04:00
The No BS Plan Report, Week 10: Where The Reliable Falter
2018-04-18T08:00:00-04:00
Your Daily Pharma Scoop: GW Pharmaceuticals' Epidiolex, Alnylam Data, Johnson & Johnson's Q1 Results
2018-04-17T11:46:21-04:00
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position
2018-04-17T07:57:11-04:00
Novocure's TTFields show positive effect in mid-stage mesothelioma study
2018-04-17T07:30:00-04:00
Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
2018-04-15T11:25:10-04:00
The No BS Report, Week 9: Mostly Holding
2018-04-13T16:30:00-04:00
Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting
2018-04-10T01:35:52-04:00
JF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
